Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
induced pluripotent stem cell-derived natural killer cells expressing soluble interleukin-15
- Development stage
- Preclinical
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intracranial, Intravenous
01
Overview
Induced pluripotent stem cell-derived natural killer cells expressing soluble interleukin-15 (iPS-NK-IL15) is an engineered cell therapy consisting of natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) and genetically modified to secrete soluble interleukin-15 (IL-15). This approach is designed to overcome the immunosuppressive tumor microenvironment, particularly in the central nervous system (CNS), where low levels of endogenous IL-15 typically limit NK cell survival, maturation, and effector function. By providing an autocrine and paracrine source of IL-15, these cells maintain high cytotoxic activity and stimulate the expansion of effector Type 1 innate lymphoid cells. This candidate is a derivative of the iPSC-NK platform (such as FT538) developed by Fate Therapeutics and is being investigated for the treatment of breast cancer brain metastasis (BCBM) and other malignancies.
- Other names
- iPS-derived NK cells expressing soluble IL-15iPSC-derived NK cells expressing soluble IL-15human iPS-derived NK cells engineered to express soluble IL15
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IgG Fc (Immunoglobulin G Fc region)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on induced pluripotent stem cell-derived natural killer cells expressing soluble interleukin-15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on induced pluripotent stem cell-derived natural killer cells expressing soluble interleukin-15.